Corporation
Vertex Pharmaceuticals (Canada) Incorporated
- Meetings this Parliament
- 15
- With MPs
- 10
- Since Nov 2021
- 24
- Active registrations
- 1
Most recent reported meeting: Sep 9, 2026.
Lobbying by Vertex Pharmaceuticals (Canada) Incorporated: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since May 3, 2026
Filed by Michael Siauw, General Manager – Canada
Lobbyists
- Kathleen Whelan · Senior Director, Government Affairs & Public Policy
- Michael Siauw · General Manager – Canada
- Prabh Grewal · Senior Manager, Policy & Corporate Communications
Institutions they may lobby: Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada
What they're lobbying on (7)Hide details
- Bill S-201, National Framework on Sickle Cell Disease Act, respecting provisions outlined in Section 2, subsections (a), (b), (e), and (i).
- Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
- Innovation, Science and Economic Development Canada Innovation and Skills Strategy and other government policies and programs related to incentivizing research and development activities in Canada.
- Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
- Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
- Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
- Common Drug Review, as it relates to health technology assessments and drug product reimbursement recommendations.
Registration 945696-366162-8. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Michael Siauw · In-house (corporation)
- Karina Gould · Member of Parliament
Bill S-201, National Framework on Sickle Cell Disease Act, respecting provisions outlined in Section 2, subsections (a), (b), (e), and (i). Read more
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
-
Reported by Michael Siauw · In-house (corporation)
- Sonia Sidhu · Member of Parliament
Bill S-201, National Framework on Sickle Cell Disease Act, respecting provisions outlined in Section 2, subsections (a), (b), (e), and (i).
-
Reported by Michael Siauw · In-house (corporation)
- Kelly DeRidder · Member of Parliament
Bill S-201, National Framework on Sickle Cell Disease Act, respecting provisions outlined in Section 2, subsections (a), (b), (e), and (i).
-
Reported by Michael Siauw · In-house (corporation)
- Juanita Nathan · Member of Parliament
- Braveenan Pradeep · Legislative Assistant, House of Commons
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases. Read more
Bill S-201, National Framework on Sickle Cell Disease Act, respecting provisions outlined in Section 2, subsections (a), (b), (e), and (i).
-
Reported by Michael Siauw · In-house (corporation)
- Dan Mazier · Member of Parliament
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
-
Reported by Michael Siauw · In-house (corporation)
- Parm Bains · Member of Parliament
- Alexander MacKenzie · Legislative Assistant, House of Commons
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
-
Reported by Michael Siauw · In-house (corporation)
- Tom Kmiec · Member of the House of Commons
Innovation, Science and Economic Development Canada Innovation and Skills Strategy and other government policies and programs related to incentivizing research and development activities in Canada. Read more
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
-
Reported by Michael Siauw · In-house (corporation)
- Tony Ince · Senator, Senate of Canada
- Venus Ramos · Parliamentary Affairs Advisor, Senate of Canada
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
-
Reported by Michael Siauw · In-house (corporation)
- Salma Zahid · Member of Parliament
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
-
Reported by Michael Siauw · In-house (corporation)
- Judy A. Sgro · Member of Parliament
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
-
Reported by Michael Siauw · In-house (corporation)
- Justine Frame · Policy Advisor, Health Canada (HC)
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
-
Reported by Michael Siauw · In-house (corporation)
- Michael Coteau · Member of Parliament
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
-
Reported by Michael Siauw · In-house (corporation)
- Sharon Burey · Senator, Senate of Canada
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
-
Reported by Michael Siauw · In-house (corporation)
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
-
Reported by Michael Siauw · In-house (corporation)
- Marie-Françoise Mégie · Senator, Senate of Canada
- Suze Youance · Senator, Senate of Canada
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
-
Reported by Michael Siauw · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
-
Reported by Michael Siauw · In-house (corporation)
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
- Sarah Polowin · Director of Parliamentary Affairs, Senate of Canada
Health
-
Reported by Michael Siauw · In-house (corporation)
- Marie-Françoise Mégie · Senator, Senate of Canada
- Nicolas Thibodeau · Parliamentary Affairs Advisor, Senate of Canada
Health
-
Reported by Michael Siauw · In-house (corporation)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
- Jed Graham · Policy Advisor, Health Canada (HC)
HealthResearch and DevelopmentScience and Technology
-
Reported by Michael Siauw · In-house (corporation)
- Daniel MacDonald · Director General, Drugs for Rare Diseases, Health Canada (HC)
- Andrew Taylor · Senior Policy Advisor, Health Canada (HC)
- Josee Leblanc · Senior Policy Advisor, Health Canada (HC)
- Christine Ung · Policy Advisor, Health Canada (HC)
HealthResearch and DevelopmentScience and Technology
-
Reported by Michael Siauw · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Darryl Patterson · Director General, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
- caroline menard · manager, Innovation, Science and Economic Development Canada (ISED)
HealthResearch and DevelopmentScience and Technology
-
Reported by Michael Siauw · In-house (corporation)
- Michael Rosu-Miles · Director, Health Canada (HC)
- Aswin Hari · Biologist/Evaluator, Health Canada (HC)
- Omar Tounekti · Manager, Gene Therapies Division, Health Canada (HC)
- Martin Nemec · Senior Biologist/Evaluator, Health Canada (HC)
and 2 moreShow fewer
- Emily Griffiths · Subject Matter / Technical Specialist, Health Canada (HC)
- Denis Arsenault · Manager - Policy Development, Health Canada (HC)
HealthResearch and DevelopmentScience and Technology
-
Reported by Michael Siauw · In-house (corporation)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
- Darryl Patterson · Director General, Innovation, Science and Economic Development Canada (ISED)
HealthResearch and DevelopmentScience and Technology
-
Reported by Michael Siauw · In-house (corporation)
- Benoit Leduc · Manager, Life Science Industries Directorate, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealthIntellectual PropertyResearch and DevelopmentScience and Technology
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.